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T
here is a pressing need for immunotherapy to
halt the progression of b-cell damage after the
onset of diabetes, and the hope is to ﬁnd a means
for reversal of the disease. However, prevention
of diabetes is equally important. Given the strength and
diversiﬁcation of a fully developed autoimmune response,
it is likely to be easier to protect from disease progression
and prevent onset of diabetes at a much earlier time point
in the disease process. The nonobese diabetic (NOD)
mouse model of human type 1 diabetes is often criticized
for the fact that many manipulations in the early phases of
disease process are successful in disease prevention. Note
that far fewer treatments are able to protect the NOD mice
at later stages of prediabetes, and even fewer reverse di-
abetes after onset of hyperglycemia (rev. in 1). However,
some treatments that have reversed diabetes in the NOD
mouse, for example anti-CD3 monoclonal antibody (2),
heat shock protein 60 peptide (3), anti-CD20 monoclonal
antibody (4), and antithymocyte globulin (5), have reached
clinical trials and had partial success. However, currently,
as we cannot know whether some preventive strategies
identiﬁed for early disease in the NOD mouse may ulti-
mately be useful in humans, it is important to continue to
study early treatments and the mechanisms by which they
work.
Although in recent years many studies have focused
on regulatory T cells that produce the immunoregulatory
cytokines interleukin (IL)-10 and transforming growth
factor-b (6), it should not be forgotten that there are other
regulatory pathways that may be harnessed for protection
against Th1-dominated autoimmune disease, in particular
a skewing to Th2 pathways. Glutamic acid decarboxylase
(GAD)-speciﬁc T-cell responses are among the earliest
noted in NOD mice (7,8). A number of investigators have
previously shown that administration of GAD/GAD pep-
tides have protected NOD mice from diabetes, particularly
when administered at a young age (9–12). A focus on GAD
is particularly interesting given the recent success in im-
munotherapy of diabetes (13) using a GAD-alum prepara-
tion in which mechanistic studies have shown immune
changes that included an increase in IL-5, IL-10, IL-13,
IL-17, interferon-g (IFN-g), and tumor necrosis factor-a.
What these changes mean in the light of a decrease in the
loss of C-peptide with time is not clear. In the NOD mouse,
a variety of therapeutic strategies using GAD and GAD
peptides have also invoked a variety of protective mech-
anisms, although it is clear that from all these studies
that a deviation toward a Th2 proﬁle has been most
prominent.
IL-13 is an important part of a Th2 response. However, it
has unique effector functions that are distinct from those
of IL-4 both in its protective qualities against gastrointes-
tinal parasites as well as in its deleterious effects in airway
hyperresponsiveness (14). There are two IL-13 receptors—
IL-13Ra1 and IL-13Ra2. IL-13Ra1 is a low-afﬁnity receptor
for IL-13 when it binds IL-13 as a homodimer. However,
when IL-13Ra1 is found as heterodimer with IL-4R, it is
ah i g h - a f ﬁnity receptor (15), the binding to which leads to
phosphorylation of signal transducer and activator of tran-
scription (STAT) 6 (16). IL-13Ra2 does not apparently sig-
nal through janus kinase/STATs (17) and is thought to be
a decoy receptor important for regulation of IL-13 (14).
In this issue, Rasche et al. (18) report a novel means by
which very early administration of GAD peptide 524-543
protects from diabetes in NOD mice. They show that in
very young NOD mice (2 weeks of age) immunized with
GAD peptide and incomplete Freund’s adjuvant, cells pro-
ducing IL-5 and IL-13 are induced, and the IL-13 reduces
spontaneous GAD responses in NOD mice. IL-13 was shown
to reduce responsiveness of polyclonal CD4 T cells and
islet-reactive BDC2.5 T cells to anti-CD3 stimulation. Of
particular interest is their other observation of a subset of
cells (about 5%) in the pancreatic lymph nodes (PLN), found
when the mice are in the early stages of insulitis, that ex-
press IL-13Ra1. It was previously thought that T cells did
not express this receptor, although more recently IL-13Ra1
has been identiﬁed on a subset of IL-17–producing cells
(16,19). However, these IL-13Ra1–positive T cells identi-
ﬁed by Rasche et al. do not produce IL-17 in this context
and thus appear to represent a newly identiﬁed novel
population of cells. It is intriguing that treatment with GAD
peptide 524-538 or 524-543 in very young mice promotes
T cells that produce IL-13 and appears to maintain the
population of IL-13Ra1 T cells in the PLN. Under normal
circumstances, the percentage of IL-13Ra1–positive cells
is high in the PLNs of 4-week-old NOD mice and it re-
duces with time in the later stages of diabetes devel-
opment in female NOD mice. Interestingly, GAD-induced
IL-13–producing cells are distinct from the IL-13Ra1–positive
T cells. Thus, it is conceivable that diabetes protection was
mediated by IL-13 that acts on the IL-13Ra1–positive T cells,
which have a protective effect (Fig. 1).
Recombinant human IL-13 protects from diabetes in the
NOD mouse (20) and attests to the potential usefulness
of IL-13 in counteracting the Th1 responses leading to di-
abetes. However, systemic administration of a beneﬁcial
cytokine that could have wide-ranging deleterious effects will
not be translatable to human therapy in this form. The fact
that an antigen-speciﬁc peptide therapy could have a very
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COMMENTARYfocused effect locally in the PLN by producing IL-13 and
maintaining a hitherto unidentiﬁed, possibly protective,
subset of cells as a mechanism of protection should be
further investigated.
Rasche et al. (18) do not comment on the effects of later
administration of GAD peptide, and they have shown pre-
viously that the treatment has greatest effect when given
early in diabetes development. It will, however, be impor-
tant to know whether such treatment could be harnessed at
a later point in the development of diabetes. More impor-
tantly, the suggestion that this treatment may maintain a
possibly protective cell population that normally decreases
with time will certainly need further exploration. It will per-
haps be particularly important to further study the IL-13Ra1–
expressing subset of T cells for regulatory properties in NOD
mice and to test whether such a population may also be
important in humans.
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FIG. 1. GAD-reactive cells stimulated on immunization of young NOD mice with incomplete Freund’s adjuvant and GAD peptide 524-543
produce IL-13. This may have many effects on a variety of tissues that include possible stimulation of a putative regulatory population
of cells that expresses IL-13Ra1. Figure includes information adapted from Wynn (14) and Rasche et al. (18). MHC, major histocom-
patibility complex; TCR, T-cell receptor.
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